Enteric Delayed-Release Granules Loading Dendrobine Ameliorates Hyperlipidemia in Mice by Regulating Intestinal Flora...

Area of Science:

• Pharmacology
• Microbiology
• Gastroenterology

Background:

• Hyperlipidemia is linked to imbalances in intestinal flora.
• Developing targeted therapies to modulate gut microbiota is crucial for managing hyperlipidemia.

Purpose of the Study:

• To create enteric delayed-release granules loaded with Dendrobine (DNL).
• To investigate the hypolipidemic effects and underlying mechanisms of DNL granules on intestinal flora in hyperlipidemic mice.

Main Methods:

• DNL was synthesized and characterized using FT-IR, XRD, SEM, and DSC.
• A hyperlipidemia mouse model was established using a high-fat diet.
• Pharmacodynamic studies and 16S rRNA high-throughput sequencing were employed to analyze gut microbiota composition and function.

Main Results:

• DNL granules significantly reduced body weight and blood lipid levels in hyperlipidemic mice (p < 0.05).
• DNL treatment modulated intestinal flora, increasing beneficial bacteria like Actinobacteria and Thick-walled bacterium.
• DNL decreased harmful bacteria such as Desulfovibrio and Mycobacterium anisopliae, thereby inhibiting pathogenic microorganisms.

Conclusions:

• Enteric delayed-release DNL granules show significant hypolipidemic efficacy.
• DNL treatment restores intestinal flora balance, suggesting a novel therapeutic strategy for hyperlipidemia.
• Modulating gut microbiota with DNL offers a promising approach to manage hyperlipidemia.